[go: up one dir, main page]

Next Issue
Volume 3, September
Previous Issue
Volume 3, March
 
 

Receptors, Volume 3, Issue 2 (June 2024) – 8 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
24 pages, 3009 KiB  
Review
Receptors Implicated in Microgravity-Induced Bone Loss
by Elizabeth Ferreira Martinez, André Antonio Pelegrine and L. Shannon Holliday
Receptors 2024, 3(2), 280-303; https://doi.org/10.3390/receptors3020014 - 13 Jun 2024
Viewed by 787
Abstract
For humans to explore and colonize the universe, both engineering and physiological obstacles must be successfully addressed. A major physiological problem is that humans lose bone rapidly in microgravity. Understanding the underlying mechanisms for this bone loss is crucial for designing strategies to [...] Read more.
For humans to explore and colonize the universe, both engineering and physiological obstacles must be successfully addressed. A major physiological problem is that humans lose bone rapidly in microgravity. Understanding the underlying mechanisms for this bone loss is crucial for designing strategies to ameliorate these effects. Because bone physiology is entangled with other organ systems, and bone loss is a component of human adaptation to microgravity, strategies to reduce bone loss must also account for potential effects on other systems. Here, we consider the receptors involved in normal bone remodeling and how this regulation is altered in low-gravity environments. We examine how single cells, tissues and organs, and humans as a whole are affected by low gravity, and the role of receptors that have been implicated in responses leading to bone loss. These include receptors linking cells to the extracellular matrix and to each other, alterations in the extracellular matrix associated with changes in gravity, and changes in fluid distribution and fluid behavior due to lack of gravity that may have effects on receptor-based signaling shared by bone and other regulatory systems. Inflammatory responses associated with the environment in space, which include microgravity and radiation, can also potentially trigger bone loss. Full article
Show Figures

Figure 1

Figure 1
<p>Simplified overview of the regulation of bone remodeling. Osteocytes positively regulate osteoclast differentiation with RANKL and negatively regulate osteoclasts with OPG. Osteocytes regulate osteoblasts with sclerostin, which blocks Wnt/beta catenin signaling, which stimulates osteoblasts to mineralize, as well as with OPG, which binds to RANKL and would be expected to inhibit RANKL reverse signaling. Osteoclasts regulate osteoblasts with RANK-containing EVs, which stimulate mineralization. RANK-EVs may also regulate osteocytes. This regulation is modified by various types of signals that either promote or inhibit bone resorption/bone formation or both. Microgravity has direct or indirect effects on most or all of the regulation. See text for detailed discussion.</p>
Full article ">Figure 2
<p>Resting and resorbing osteoclasts. (<b>A</b>,<b>B</b>). Inactive osteoclast on coverslip stained with phalloidin to detect actin filaments (green) and anti-E subunit of V-ATPase (red). V-ATPase is present in vesicles in the cytosol. Actin filaments are spread through the cytosol and an actin belt is located at the periphery of the cell (arrows). (<b>C</b>,<b>D</b>.) Resorbing osteoclasts on a bone slice. The actin ring is not at the periphery of the cell (arrows). Outside the actin ring attachments are made between the cells and the bone with integrins and bone matrix. These resist the force produced by the actin ring pushing the membrane into the bone. V-ATPase is in the plasma membrane (ruffled border) which is bounded by the actin ring. A second smaller resorbing osteoclast is on the upper left of (<b>C</b>,<b>D</b>). Scale bar = 100 microns in (<b>A</b>,<b>B</b>) and 20 microns in (<b>C</b>–<b>E</b>). Schematic of a vertical section through a resorbing osteoclast. The flesh color is bone, red is the acidified resorption compartment. V-ATPases (small dark blue circles) stud the ruffled border. Light blue is the osteoclast, dark blue is nuclei, and green is the extracellular milieu.</p>
Full article ">Figure 3
<p>Osteoblast differentiation and mechanism by which osteoblasts mineralize bone: (<b>A</b>) Osteoblasts differentiate from multipotent mesenchymal stem cells through a number of steps. The schematic shows transcription factors that are crucial and signaling molecules involved. Note that while Wnt/β-catenin is vital for osteoblast differentiation, various other factors contribute to differentiation. Each differentiation stage contributes differently to signaling that occurs in the local bone microenvironment. Osteocytes, the final differentiation stage of the osteoblast and the most abundant cells in bone modulate the differentiation of the immature osteoblasts at every stage. (<b>B</b>) PILP mineralization mechanism: 1. A protein with a stretch of acidic amino acids and calcium ions. 2. The acidic region recruits calcium ions. 3. A larger shell of calcium ions, phosphate ions, and water; the PILP droplet develops. This infiltrates the collagen matrix and then forms a nano-crystal within the matrix. Altered fluid dynamics may affect this crystallization process. It is known that larger and more symmetrical crystals are formed in microgravity. Subtle alterations in PILP crystallization (for example, the formation of slightly larger crystals) could have profound consequences for the quality of bone.</p>
Full article ">Figure 4
<p>Sclerostin blocks Wnt/β-catenin signaling. When Wnt binds LRP5 or LRP6, Frizzled is recruited and β-catenin stimulates nuclear genes that, ultimately, promote bone formation. When sclerostin binds LRP5 or LRP6 in place of Wnt, Frizzled is not recruited, and β-catenin is degraded. Bone formation is blocked and increased bone resorption occurs.</p>
Full article ">Figure 5
<p>Extracellular vesicles containing RANKL or RANK add increased complexity to the RANKL/RANK/osteoprotegerin signaling network that is at the core of bone biology. Until recently, RANKL stimulation of RANK to stimulate osteoclast formation and bone resorption by osteoclasts, and the ability of osteoprotegerin to bind RANKL and competitively inhibit this signaling, were considered the primary features of this network. Now, it is known that osteocytes contribute most of the RANKL to stimulate osteoclasts, either directly or by producing RANKL-EVs. RANKL-EVs can stimulate osteoclast formation and bone resorption through RANK stimulation, and RANK-EVs bind to RANKL on osteoblasts to stimulate RANKL reverse signaling and bone formation. The latter serves to couple bone resorption and bone formation. It is also possible that RANK-EVs can bind RANKL or RANKL-EVs and competitively inhibit their stimulation of RANK on osteoclasts. RANKL-EVs could serve as competitive inhibitors of RANK-EV’s stimulation of RANKL reverse signaling.</p>
Full article ">Figure 6
<p>Pattern of bone loss in humans subjected to microgravity. Green indicates bone gain, light blue denotes modest bone loss, and red indicates severe bone loss. The intensity of this pattern varies significantly between individuals.</p>
Full article ">
25 pages, 2653 KiB  
Review
Deciphering the Role of Virus Receptors in Plant–Virus–Vector Interactions
by Sumit Jangra, Senthilraja Chinnaiah, Sneha Rashtrapal Patil, Bhavya Shukla, Ragunathan Devendran and Manish Kumar
Receptors 2024, 3(2), 255-279; https://doi.org/10.3390/receptors3020013 - 3 Jun 2024
Viewed by 963
Abstract
Insect-transmitted plant viruses are a major threat to global agricultural crop production. Receptors play a prominent role in the interplay between host-pathogen and vector interaction. The virus–vector relationship involves both viral and vector receptors. Receptors-like kinases (RLKs) and receptor-like proteins play a crucial [...] Read more.
Insect-transmitted plant viruses are a major threat to global agricultural crop production. Receptors play a prominent role in the interplay between host-pathogen and vector interaction. The virus–vector relationship involves both viral and vector receptors. Receptors-like kinases (RLKs) and receptor-like proteins play a crucial role in plant immunity, which acts as a basal defense. Pathogens can evade or block host recognition by their effector proteins to inhibit pathogen recognition receptor (PRR)-mediated signaling. Intriguingly, RLKs are also known to interact with viral proteins and impact plant susceptibility against viruses, while the endocytic receptors in vectors assist in the binding of the virus to the vectors. Unlike other receptors of fungi and bacteria which have three different domains located from extracellular or intracellular to perceive a multitude of molecular patterns, the characterization of viral receptors is quite complex and limited since the virus is directly injected into plant cells by insect vectors. Little is known about these receptors. Unraveling the receptors involved in virus entry and transmission within the vector will provide vital information in virus–vector interactions. This review focuses on efforts undertaken in the identification and characterization of receptors of plant viruses within the host and vector. This will lead to a better understanding of the cellular mechanism of virus transmission and spread, and further suggests new alternative tools for researchers to develop an integrated approach for the management of viral diseases and associated vectors. Full article
Show Figures

Figure 1

Figure 1
<p>Schematic representation of some of the common techniques used for the identification and functional characterization of proteins associated with plant–virus–vector pathosystem.</p>
Full article ">Figure 2
<p>A schematic diagram of an aphid showing the putative proteins corresponding to viral interactive partners. Barley yellow dwarf virus (BYDV), cauliflower mosaic virus (CaMV), zucchini yellow mosaic virus (ZYMV), and tobacco etch virus (TEV) are shown in combination with their putative partners. Host proteins are represented as non-glycosylated proteins (NGPs), Cuticular proteins (CuPs), ribosomal protein S2 (RPS2), and complement component 1Q subcomponent-binding protein (C1QBP). The presence of the viral receptors in aphids is shown with star shapes and different colors.</p>
Full article ">Figure 3
<p>A schematic diagram of planthopper showing the putative proteins corresponding to viral interactive partners. Tomato yellow leaf curl virus (TYLCV), rice stripe virus (RSV), and rice ragged stunt oryzavirus (RRSV) are shown in combination with their putative partners. Insect proteins such as vitellogenin (Vg), G-protein Pathway Suppressor 2 (GPS2), oligomycin-sensitivity conferral protein (OSCP), sugar transporter 6 (STP), and flotillin are shown in combination with their respective viruses. The presence of the viral receptors in the planthopper is shown with star shapes and different colors.</p>
Full article ">Figure 4
<p>A schematic diagram of thrips showing the putative proteins corresponding to viral interactive partners. Tomato spotted wilt virus (TSWV) with midgut proteins, endocuticle structural glycoprotein (Fo-GN), cyclophilin (Fo-Cyp1), apolipoprotein-D (ApoD), orai-2-like (Orai), and obstructor-E-like isoform X2 (Obst). Major segments like the head, thorax, and abdomen are labeled. The presence of the viral receptors in thrips is shown with different colors and shapes.</p>
Full article ">Figure 5
<p>A schematic diagram of a whitefly showing the putative proteins corresponding to viral interactive partners. Tomato yellow leaf curl virus (TYLCV), tomato leaf curl New Delhi virus (ToLCVNDV), cotton leaf curl Rajasthan virus (CLCuV-Ra), cotton leaf curl Multan virus (CLCuMuV), and tomato yellow leaf curl Sardinia virus (TYLCSV). Insect proteins are heat-shock proteins (BtHSP16 and BtHSP70), <span class="html-italic">B. tabaci</span> peptidoglycan recognition protein (BtPGRP), Cyclophilin (Cyp) B, midgut protein (MGP), vesicle-associated membrane protein-associated protein B (VAPB), proliferating cell nuclear antigen (PCNA), cubilin (BtCUBN), aminoless (BtAMN), <span class="html-italic">B. tabaci</span> vesicle-associated membrane protein 2 (BtVAMP2), vacuolar protein (Vps), sorting-associated protein twenty-associated 1 (Vta1), and phosphatidylethanolamine-binding protein (PEBP). Major segments like the head, thorax, and abdomen are labeled.</p>
Full article ">Figure 6
<p>A simplified diagram of virus and non-virus-associated receptors in plants. <span class="html-italic">N</span>-gene, <span class="html-italic">Rx</span> gene, <span class="html-italic">Sw-5b</span> gene, <span class="html-italic">RCY1</span> gene, <span class="html-italic">Tm-1</span>, <span class="html-italic">RTM1/RTM2</span> gene show the response against viruses. Tobacco mosaic virus (TMV), potato virus X (PVX), tomato spotted wilt virus (TSWV), cucumber mosaic virus (CMV), tomato mosaic virus (ToMV), and tobacco etch virus (TEV) are interacting with host proteins. Other non-NBS-LRR receptors are also shown in this image.</p>
Full article ">
35 pages, 5518 KiB  
Review
The G Protein-Coupled Estrogen Receptor GPER in the Development and Progression of Cancer
by Liliana Torres-López, Miguel Olivas-Aguirre and Oxana Dobrovinskaya
Receptors 2024, 3(2), 220-254; https://doi.org/10.3390/receptors3020012 - 27 May 2024
Viewed by 1183
Abstract
The high incidence of cancer and the prevalence of chemoresistance are serious problems worldwide, underscoring the urgency of novel research focused on understanding the underlying mechanisms and finding new therapeutic targets. Recently, the G protein-coupled estrogen receptor (GPER) has received increasing attention, and [...] Read more.
The high incidence of cancer and the prevalence of chemoresistance are serious problems worldwide, underscoring the urgency of novel research focused on understanding the underlying mechanisms and finding new therapeutic targets. Recently, the G protein-coupled estrogen receptor (GPER) has received increasing attention, and it has been studied in various models, including physiological and pathological conditions, using appropriate pharmacological and molecular biological strategies. Numerous studies indicate that GPER plays an important role in cancer progression and resistance. This review focuses on the structure of GPER, the diversity of its ligands and GPER-activated signaling pathways, the role of GPER in cancer progression, and mechanisms of chemoresistance, with special emphasis on different cancer types and the tumor microenvironment. GPER was evidenced to exhibit conformational plasticity and different ligand binding modes. Therefore, GPER-mediated effects can be triggered by estrogens or various estrogen mimetics, including synthesized compounds, licensed drugs, or exogenous environmental compounds. We found multiple reports evidencing that GPER is differentially expressed in healthy tissues and tumors and plays a protumor role in breast, ovarian, lung, thyroid, and endometrial cancers. Additionally, there are several studies that indicate that GPER expression in cells of the tumor microenvironment may also contribute to cancer progression. Among the major mechanisms of GPER-mediated chemoresistance are the epithelial-mesenchymal transition, the overexpression of multidrug resistance pumps, and autophagy regulation. Full article
Show Figures

Figure 1

Figure 1
<p>Sites of interaction with ligands in the amino acid sequence of GPER. The amino acid sequence corresponding to GPER was obtained from the Uniprot database (accession number: Q6FHU6). Transmembrane domains (TM1–7) are marked in different colors. The amino-terminal (N-terminal), carboxyl-terminal (C-terminal), and intra- and extracellular loops are indicated. The chemical structures of some known GPER ligands are presented in the right panel. Each ligand is assigned a specific circle that appears at the corresponding interaction site on the GPER amino acid sequence in the left panel.</p>
Full article ">Figure 2
<p>Biological effects and activation pathways of non-canonical GPER ligands. Agonists are connected to GPER by a green arrow, while antagonists’ inhibition are indicated by a red. Each ligand is assigned a number that appears in the corresponding signaling pathway activated by that ligand, as well as in the box with the biological effect into which those pathways are translated.</p>
Full article ">Figure 3
<p>GPER-activated pathways related to chemoresistance. The different pathways are assigned different numbers and colors: (1) upregulation of ATP binding cassette subfamily G member 2 (ABCG2; black arrows), (2) favoring the epithelial–mesenchymal transition (EMT; green arrows), and (3) induction of autophagy (blue arrows). Autophagy inhibition by mTOR is indicated in red.</p>
Full article ">Figure 4
<p>Role of GPER in different cancer types. For enhanced comprehension, attending to the figure code located in the lower section of the figure is strongly recommended. The “Localization” column (grey) provides a simplified depiction of cellular compartments (nucleus, plasma membrane, or cytosol), with red color highlighting confirmed GPER expression in the corresponding model (consult <a href="#receptors-03-00012-t002" class="html-table">Table 2</a> for further information). In the “Primary tumor” column (yellow), GPER expression is examined for each specific cancer type. Columns highlighted in red delineate cancerous processes influenced by GPER expression or GPER activation by ligands. The blue column denotes the overall significance of GPER expression concerning the prognosis of the respective cancer type.</p>
Full article ">
19 pages, 3011 KiB  
Article
An Evaluation of the Anxiolytic Potential of Amentoflavone in Adult Zebrafish Undergoing Alcohol Withdrawal: In Vivo and In Silico Studies
by Lucas Soares Frota, Wildson Max Barbosa da Silva, Daniela Ribeiro Alves, Sacha Aubrey Alves Rodrigues Santos, Gabriela Alves do Nascimento, Francisco Ernani Alves Magalhães, Adriana Rolim Campos and Selene Maia de Morais
Receptors 2024, 3(2), 201-219; https://doi.org/10.3390/receptors3020011 - 10 May 2024
Viewed by 1069
Abstract
The constant use of alcoholic beverages can deregulate serotonin levels, affecting neurotransmitters and triggering symptoms of anxiety. In this context, the objective of this work was to evaluate the anxiolytic potential and possible action mechanisms of the natural compound amentoflavone against the deleterious [...] Read more.
The constant use of alcoholic beverages can deregulate serotonin levels, affecting neurotransmitters and triggering symptoms of anxiety. In this context, the objective of this work was to evaluate the anxiolytic potential and possible action mechanisms of the natural compound amentoflavone against the deleterious effects caused by alcohol withdrawal on the behavior of adult zebrafish (aZF). The experiments showed that amentoflavone did not change locomotion and did not cause toxicity in aZF during up to 96 h of analysis, with a median lethal concentration (LC50) greater than 1.0 mg/mL. The reversal of anxiety by pretreatment with granisetron suggested that the anxiolytic effect of amentoflavone is dependent on serotonergic 5-HT3A/3B receptors. Furthermore, amentoflavone reversed anxiety due to flumazenil pretreatment, suggesting a dependence on the GABAA receptor. The three concentrations of amentoflavone tested were effective in treating anxiety resulting from alcohol withdrawal. In silico analysis validated the in vivo results, supporting the idea that the interaction of amentoflavone with the protein occurs in a more stable manner than reference compounds. Amid growing interest in natural alternatives to treat anxiety disorders, amentoflavone is a potential candidate for a new anxiolytic compound that acts specifically on the 5HT3A/3B and GABAergic serotonergic pathways. Full article
Show Figures

Figure 1

Figure 1
<p>The chemical representation of the structure of the biflavonoid amentoflavone (AMT).</p>
Full article ">Figure 2
<p>Protocol summary. A brief summary of the experimental protocol and behavioral analyses performed in this study.</p>
Full article ">Figure 3
<p>Anxiolytic-like effect of biflavonoid AMT in adult zebrafish (<span class="html-italic">Danio rerio</span>) in Light and Dark Test (0–5min). Naive—untreated animals. Vehicle—3% DMSO (20 µL; i.p.). DZP—diazepam (10 mg/mL; 20 µL; i.p.). Values represent mean ± standard error of mean (S.E.M.) for 6 animals/group. ANOVA followed by Tukey test (**** <span class="html-italic">p</span> &lt; 0.001 vs. naive or vehicle).</p>
Full article ">Figure 4
<p>The effect of cyproheptadine (Cypro; 0.8 mg/mL; p.o.) on the anxiolytic-like effect of the biflavonoid AMT (0.01 mg/mL; i.p.) in adult zebrafish (<span class="html-italic">Danio rerio</span>) in the Light and Dark Test (0—5min). Naive—untreated animals. Flx—fluoxetine (1.25 × 10<sup>−3</sup> mg/mL; i.p.). Vehicle—3% DMSO (20 µL; i.p.). Values represent the mean ± the standard error of the mean (S.E.M.) for 6 animals/group. ANOVA followed by the Tukey test (**** <span class="html-italic">p</span> &lt; 0.001 vs. naive or vehicle; <b><sup>####</sup></b> <span class="html-italic">p</span> &lt; 0.001 vs. Flx; <sup>ns</sup> <span class="html-italic">p &gt;</span> 0.05 vs. AMT).</p>
Full article ">Figure 5
<p>The effect of pizotifen (Piz; 0.8 mg/mL; p.o.) on the anxiolytic-like effect of the biflavonoid AMT (0.01 mg/mL; p.o.) in adult zebrafish (<span class="html-italic">Danio rerio</span>) in the Light and Dark Test (0–5 min). Naive—untreated animals. Flx—fluoxetine (1.25 × 10<sup>−3</sup> mg/mL; i.p.). Vehicle—3% DMSO (20 µL; i.p.). Values represent the mean ± the standard error of the mean (S.E.M.) for 6 animals/group. ANOVA followed by the Tukey test (** <span class="html-italic">p</span> &lt; 0.01; **** <span class="html-italic">p</span> &lt; 0.0001 vs. naive or vehicle; <b><sup>####</sup></b><span class="html-italic">p</span> &lt; 0.0001 vs. Flx; <sup>ns</sup> <span class="html-italic">p &gt;</span> 0.05 vs. AMT).</p>
Full article ">Figure 6
<p>The effect of granisetron (Gstn; 0.5 mg/mL; p.o.) on the anxiolytic-like effect of the biflavonoid AMT (0.01 mg/mL; i.p.) in adult zebrafish (<span class="html-italic">Danio rerio</span>) in the Light and Dark Test (0–5 min). Naive—untreated animals. Flx—fluoxetine (1.25 × 10<sup>−3</sup> mg/mL; i.p.). Vehicle—3% DMSO (20 µL; i.p.). Values represent the mean ± the standard error of the mean (S.E.M.) for 6 animals/group. ANOVA followed by the Tukey test (**** <span class="html-italic">p</span> &lt; 0.0001 vs. naive or vehicle; <b><sup>####</sup></b> <span class="html-italic">p</span> &lt; 0.0001 vs. AMT or Flx).</p>
Full article ">Figure 7
<p>The effect of flumazenil (Fmz; 0.1 mg/mL; i.p.) on the anxiolytic-like effect of AMT biflavonoids (0.01 mg/mL; i.p.) in adult zebrafish (<span class="html-italic">Danio rerio</span>) in the Light and Dark Test (0–5 min). Naive—untreated animals. DZP—diazepam (10 mg/mL; p.o.). Vehicle—3% DMSO (20 µL; p.o.). Values represent the mean ± the standard error of the mean (S.E.M.) for 6 animals/group. ANOVA followed by the Tukey test (**** <span class="html-italic">p</span> &lt; 0.0001 vs. naive or vehicle; <b><sup>####</sup></b> <span class="html-italic">p</span> &lt; 0.0001 vs. AMT or DZP).</p>
Full article ">Figure 8
<p>The effect of AMT (C1—0.01 or C2—0.1 or C3—1.0 mg/mL; 20 µL; i.p.) on the treatment of anxiety in adult zebrafish (11th day), induced by abstinence from alcohol (EtOH 38%) in the Light and Dark Test (0–5 min). G—group. C—concentration. Naive—untreated animals (control). ACAA—yellow cane spirit (20 µL; p.o.). Vehicle—3% DMSO (20 µL; i.p.). DZP—diazepam (10 mg/mL; 20 µL; i.p.). Values represent the mean ± the standard error of the mean (S.E.M.) for 6 animals/group. ANOVA followed by the Tukey test (** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001 vs. naive, vehicle or ACAA).</p>
Full article ">Figure 9
<p>The effect of the biflavonoid AMT on the locomotor activity of adult zebrafish (<span class="html-italic">Danio rerio</span>) in the open field test (0–5 min). Naive—untreated animals. DZP—diazepam (10 mg/mL; 20 µL; i.p.). Vehicle—3% DMSO (20 µL; i.p.). Values represent the mean ± the standard error of the mean (S.E.M.) for 6 animals/group. ANOVA followed by the Tukey test (**** <span class="html-italic">p</span> &lt; 0.0001 vs. naive or vehicle; <sup>####</sup> <span class="html-italic">p</span> &lt; 0.0001 vs. DZP).</p>
Full article ">Figure 10
<p>The effect of the biflavonoid AMT on convulsive activity (clonus and loss of posture) in adult zebrafish (<span class="html-italic">Danio rerio</span>) induced by pentylenetetrazole (PTZ). Vehicle—3% DMSO (20 µL; i.p.); DZP—diazepam (10 mg/mL; 20 µL; i.p.). Values represent the mean ± the standard error of the mean (S.E.M.) for 6 animals/group. ANOVA followed by the Tukey test (**** <span class="html-italic">p</span> &lt; 0.0001 vs. control; <sup>####</sup> <span class="html-italic">p</span> &lt; 0.0001 vs. DZP).</p>
Full article ">Figure 11
<p>Representation of AMT (red), Flx (blue), Gstn (green) on target 5HT<sub>3A</sub>.</p>
Full article ">Figure 12
<p>Representation of AMT (red), DZP (blue), Fmz (green) on GABA<sub>A</sub> target.</p>
Full article ">
19 pages, 1581 KiB  
Review
Estrogen Signals through ERβ in Breast Cancer; What We Have Learned since the Discovery of the Receptor
by Harika Nagandla and Christoforos Thomas
Receptors 2024, 3(2), 182-200; https://doi.org/10.3390/receptors3020010 - 3 May 2024
Viewed by 1446
Abstract
Estrogen receptor (ER) β (ERβ) is the second ER subtype that mediates the effects of estrogen in target tissues along with ERα that represents a validated biomarker and target for endocrine therapy in breast cancer. ERα was the only known ER subtype until [...] Read more.
Estrogen receptor (ER) β (ERβ) is the second ER subtype that mediates the effects of estrogen in target tissues along with ERα that represents a validated biomarker and target for endocrine therapy in breast cancer. ERα was the only known ER subtype until 1996 when the discovery of ERβ opened a new chapter in endocrinology and prompted a thorough reevaluation of the estrogen signaling paradigm. Unlike the oncogenic ERα, ERβ has been proposed to function as a tumor suppressor in breast cancer, and extensive research is underway to uncover the full spectrum of ERβ activities and elucidate its mechanism of action. Recent studies have relied on new transgenic models to capture effects in normal and malignant breast that were not previously detected. They have also benefited from the development of highly specific synthetic ligands that are used to demonstrate distinct mechanisms of gene regulation in cancer. As a result, significant new information about the biology and clinical importance of ERβ is now available, which is the focus of discussion in the present article. Full article
Show Figures

Figure 1

Figure 1
<p>Flow chart depicting effects of ERβ on EMT, cell migration and metastasis in breast cancer. Cystatins 1, 2, 4 and 5 are direct targets of ERβ in triple negative breast cancer (TNBC) cells. Expression of ERβ in TNBC cells followed by agonist activation inhibits metastasis in vivo by inducing the expression of cystatins that downregulate TGFβ signaling. Beclin-1, a key regulator of autophagy is upregulated by Claudin-6, a direct target of ERβ in breast cancer. Claudin-6 inhibits breast cancer cell migration and invasion. ERβ represses transcription of the activators of the cytoskeleton remodeler RhoC, ELMO1 and GRP141, by directly binding to their regulatory regions, thereby preventing RhoC activation and actin-based cell migration. Approximately 80% of TNBCs harbor oncogenic mutations of p53. ERβ directly interacts with mutant p53 and inhibits its pro-metastatic signaling. ERβ also inhibits epithelial–mesenchymal transition (EMT) by inducing EGFR degradation that results in upregulation of the epithelial markers miR-200a-b-429 and E-cadherin.</p>
Full article ">Figure 2
<p>Structural and functional domains of estrogen receptor β. Domains are shown for both the full length ERβ (also called ERβ1) and its isoforms ERβ2-5. Numbers indicate amino acid length of individual domains and the full length proteins. All ERβ isoforms are identical until the hinge region, where they begin diverging from the C-terminal of the ligand-binding domain (LBD). The ligand-independent transactivation function (AF-1) resides in the N-terminus of the receptor and serves as an interaction site for regulatory factors. The DNA-binding domain (DBD) recognizes estrogen response elements (ERE) in regulatory regions of target genes, whereas the hinge region harbors a nuclear localization signal (NLS). The LBD consists of the ligand-binding transactivation function (AF-2) and provides an interface for receptor dimerization and co-activator binding.</p>
Full article ">Figure 3
<p>Chemical structure of synthetic ligands of estrogen receptors tamoxifen, raloxifene and LY500307.</p>
Full article ">Figure 4
<p>Anti-tumor activities of the selective ERβ agonist LY500307. (<b>A</b>) Activating ERβ with LY500307 enables triple negative breast cancer (TNBC) and melanoma cells to secrete interleukin-1β (IL-1β), which stimulates the recruitment of anti-tumor neutrophils to the metastatic niche suppressing lung metastasis. (<b>B</b>) Similar to TNBC, ERβ and LY500307 prevent lung metastasis in inflammatory breast cancer (IBC) by inhibiting actin-based cell migration through the repression of the direct targets GPR141 and ELMO1 that activate the cytoskeleton remodeler RhoC. (<b>C</b>) Activation of ERβ with LY500307 also inhibits tumor growth and increases the survival of mice with highly aggressive glioblastoma (GBM) by reducing cell proliferation and inducing cell cycle arrest and apoptosis. (<b>D</b>) LY500307 greatly improves the therapeutic efficacy of immune checkpoint blockade (ICB) therapy with anti-PDL1 antibodies in TNBC and colorectal cancer. Activating ERβ in tumor cells with LY500307 prevents them from secreting CSF-1 in the tumor microenvironment, thus diminishing the recruitment of myeloid-derived suppressor cells (MDSCs), which, along with increased CD8<sup>+</sup> T cells, leads to smaller tumors in mice. → and <b>⊥</b> represent positive and negative regulation, respectively and Red X indicates blockade.</p>
Full article ">
27 pages, 490 KiB  
Review
Dopamine D1–D5 Receptors in Brain Nuclei: Implications for Health and Disease
by Ichiro Kawahata, David I. Finkelstein and Kohji Fukunaga
Receptors 2024, 3(2), 155-181; https://doi.org/10.3390/receptors3020009 - 12 Apr 2024
Cited by 2 | Viewed by 2097
Abstract
Understanding the intricate role of dopamine D1–D5 receptors is pivotal in addressing the challenges posed by the aging global population, as well as by social stress and advancing therapeutic interventions. Central to diverse brain functions such as movement, cognition, motivation, and reward, dopamine [...] Read more.
Understanding the intricate role of dopamine D1–D5 receptors is pivotal in addressing the challenges posed by the aging global population, as well as by social stress and advancing therapeutic interventions. Central to diverse brain functions such as movement, cognition, motivation, and reward, dopamine receptors are ubiquitously distributed across various brain nuclei. This comprehensive review explores the nuanced functions of each dopamine receptor, D1, D2, D3, D4, and D5, in distinct brain regions, elucidating the alterations witnessed in several neurological and psychiatric disorders. From the substantia nigra and ventral tegmental area, crucial for motor control and reward processing, to the limbic system influencing emotional responses, motivation, and cognitive functions, each brain nucleus reveals a specific involvement of dopamine receptors. In addition, genetic variations in dopamine receptors affect the risk of developing schizophrenia and parkinsonism. The review further investigates the physiological significance and pathogenic impacts of dopamine receptors in critical areas like the prefrontal cortex, hypothalamus, and striatum. By unraveling the complexities of dopamine receptor biology, especially those focused on different brain nuclei, this review provides a foundation for understanding their varied roles in health and disease, which is essential for the development of targeted therapeutic strategies aimed at mitigating the impact of aging and mental health on neurological well-being. Full article
10 pages, 1814 KiB  
Review
Exploring Emerging Therapeutic Targets and Opportunities in Neuroendocrine Tumors: Updates on Receptor Tyrosine Kinases
by Lara Toffoli, Angeliki Ditsiou and Teresa Gagliano
Receptors 2024, 3(2), 145-154; https://doi.org/10.3390/receptors3020008 - 5 Apr 2024
Cited by 1 | Viewed by 1151
Abstract
Neuroendocrine tumors (NETs) represent a diverse group of neoplasms originating from neuroendocrine cells, presenting varied clinical behaviors and posing significant challenges in management. This review explores the emerging roles of receptor tyrosine kinases (RTKs) in the pathogenesis and progression of NETs, including vascular [...] Read more.
Neuroendocrine tumors (NETs) represent a diverse group of neoplasms originating from neuroendocrine cells, presenting varied clinical behaviors and posing significant challenges in management. This review explores the emerging roles of receptor tyrosine kinases (RTKs) in the pathogenesis and progression of NETs, including vascular endothelial growth factor receptors (VEGFRs), insulin-like growth factor receptors (IGF-1R), RET, epidermal growth factor receptor (EGFR), and ALK. The dysregulation of RTK signaling pathways contributes to key cellular processes such as proliferation, survival, and invasion in NETs. We discuss the potential of targeting RTKs as therapeutic strategies in NETs, with a focus on recent developments in RET inhibitors and the therapeutic implications of RTK alterations. Full article
Show Figures

Figure 1

Figure 1
<p>IGF-1R activation and pathway in NET cells. The complex interactions and downstream effects initiated by IGF-1R activation, highlighting its central role in regulating key cellular processes such as proliferation, survival, and differentiation within NETs.</p>
Full article ">Figure 2
<p>VEGF ligands and receptors, activation pathway in NETs cells. The diagram outlines the activation pathways of vascular endothelial growth factor (VEGF) ligands and their receptors in neuroendocrine tumor (NET) cells. The figure delineates the interactions between VEGFR1, VEGFR2, and VEGFR3 receptors and their respective ligands, including VEGF-A, VEGF-B, VEGF-C, and VEGF-D. Through intricate signaling cascades, these ligands activate their corresponding receptors, leading to the modulation of angiogenesis and various cellular processes crucial for NET pathogenesis.</p>
Full article ">Figure 3
<p>RET and its mutation/fusion in NETs cells. RET wild-type, mutated, and fusion protein variants of the RET receptor tyrosine kinase in neuroendocrine tumors (NETs). The diagram delineates the structural differences between the wild-type RET protein and its mutated counterparts, highlighting specific amino acid alterations associated with mutations. Additionally, the figure illustrates fusion proteins resulting from genetic rearrangements involving RET, such as RET fusion with other genes.</p>
Full article ">Figure 4
<p>ALK and EGFR pathway in NET. An overview of the various forms of the ALK (anaplastic lymphoma kinase) and EGFR (epidermal growth factor receptor) proteins observed in neuroendocrine tumors (NETs). The diagram illustrates wild-type (wt) ALK and EGFR proteins, as well as mutated and fusion variants resulting from genetic alterations.</p>
Full article ">
23 pages, 4948 KiB  
Review
Molecular Targets for Cannabinoids in Natural Killer Cells: Do They Modulate the Antitumor Activity?
by Miguel Olivas-Aguirre, Cecilia Gutiérrez-Iñiguez, Igor Pottosin and Oxana Dobrovinskaya
Receptors 2024, 3(2), 122-144; https://doi.org/10.3390/receptors3020007 - 25 Mar 2024
Cited by 2 | Viewed by 1402
Abstract
Recent research has emphasized the potential of natural and synthetic cannabinoids as anticancer agents. Yet it remains unclear whether and in which sense cannabinoids affect the anticancer activity of NK cells, an important branch of anticancer immunity. Similar uncertainty exists regarding NK cells-based [...] Read more.
Recent research has emphasized the potential of natural and synthetic cannabinoids as anticancer agents. Yet it remains unclear whether and in which sense cannabinoids affect the anticancer activity of NK cells, an important branch of anticancer immunity. Similar uncertainty exists regarding NK cells-based immunotherapy. Here we presented an overview of multiple cannabinoid targets as canonical (mainly CB2) and non-canonical receptors, ion channels, transporters, and enzymes, expressed in NK cells, along with underlying molecular mechanisms. Through them, cannabinoids can affect viability, proliferation, migration, cytokine production, and the overall anticancer activity of NK cells. Respective holistic studies are limited, and, mostly, are phenomenological, not linking observed effects with certain molecular targets. Another problem of existing studies is the lack of standardisation, so that diverse cannabinoids at variable concentrations and ways of administration are applied, and often, instead of purified NK cells, the whole lymphocyte population is used. Therefore, there is an urgent need for more focused, systemic, and in-depth studies of the impact of the cannabinoid toolkit on NK cell function, to critically address the compatibility and potential synergies between NK activity and cannabinoid utilization in the realm of anticancer interventions. Full article
Show Figures

Figure 1

Figure 1
<p>Overview of the cannabinoid types. The structure of representative phytocannabinoids (green; <b>left</b>), endocannabinoids (orange, <b>center</b>), and synthetic cannabinoids (grey, <b>right</b>) are provided. Further details and additional characteristics for each cannabinoid can be accessed online through the PubChem database [<a href="#B11-receptors-03-00007" class="html-bibr">11</a>].</p>
Full article ">Figure 2
<p>Overview of the classical and non-classical CBRs in NK cells. (<b>A</b>) Classification of the proteins targeted by cannabinoids in NK cells. (<b>B</b>) Subcellular location of the CBRs in NK cells. (<b>C</b>) Processes regulated by the reported CBRs in NK cells. Color code: CBRs were colored only when their subcellular localization was appropriately validated for NK cells, whereas grey-coded CBRs represent functionally expressed ones with the suggested location, based on the data from the protein atlas [<a href="#B24-receptors-03-00007" class="html-bibr">24</a>] (see details in <a href="#app1-receptors-03-00007" class="html-app">Supplementary Table S1</a>).</p>
Full article ">Figure 3
<p>Role of the ion channels present in NK cells in the regulation of intracellular calcium and NK cell function. (1) NK cell activation results in the formation of the immunological synapse (IS), promoting the intracellular downstream signaling, which results in the production of IP<sub>3</sub> and consequent Ca<sup>2+</sup> release from the ER. (2) Depletion of ER Ca<sup>2+</sup> induces STIM conformational change, resulting in the interaction of STIM with Orai subunits, to assemble the functional CRAC channel, which promotes Ca<sup>2+</sup> entry (SOCE). (3) K<sup>+</sup> channels functionally interact with CRAC by mediating K<sup>+</sup> efflux and promoting hyperpolarization to sustain CRAC activity. (4) Mitochondria are recruited upon IS formation and contribute to preserve CRAC activity by taking up high amounts of Ca<sup>2+</sup> to limit CRAC inactivation. Additionally, mitochondrial Ca<sup>2+</sup> uptake favors the cell´s metabolism, necessary for its effector function (e.g., migration, degranulation). (5) Intracellular Ca<sup>2+</sup> rise triggers the expression of multiple genes involved in NK cell activation, proliferation, and function. (6) The magnitude of intracellular Ca<sup>2+</sup> rise determines the efficiency of the lytic granule release (see text for details). (7) The contribution of TRP family members, nAChR, and GABA<sub>A</sub>, to the global Ca<sup>2+</sup> signal can impact the NK cells’ response to target cells. Blue circles depict Ca<sup>2+</sup> ion. Yellow signs (!) indicate ion channels, expressed in NK cells, which are regulated by cannabinoids (see text for the details of regulation). Pink rectangles represent perforin, whereas yellow circles represent granzymes.</p>
Full article ">Figure 4
<p>Model for cannabinoid-induced sensitization of malignant NK cells to chemotherapy. (A) Tumoral NK cells exposed to chemotherapy overexpress proteins belonging to the cytochrome P450 superfamily (CYPs), which metabolize common chemotherapeutics to promote a pro-tumorigenic state. Additionally, they express high levels of P-gp and ABCG2, both acting as efflux systems for chemotherapeutics. (B) Cannabinoids, mainly from plant sources, act as P-gp, ABC2G, and CYP inhibitors, which enable maximum retention of chemotherapeutics in NK tumor cells, limiting tumor growth.</p>
Full article ">Figure 5
<p>NK cytotoxic activity against target cells and its modulation by cannabinoids. The effector response of NK cells is a multistep process. First, NK cells recognize the target cell through the interaction of surface molecules, forming the immunological synapse (IS). Protein clustering at the IS promotes the intracellular cell signaling that includes Ca<sup>2+</sup><sub>i</sub> elevation, cytoskeleton reorganization, and gene expression. As an early response, lytic granules, containing granzymes and perforin, are released. A long-term response involves the production and release of cytokines and chemokines with autocrine and paracrine activities. Numbers indicate the steps at which cannabinoids have been demonstrated to act as regulators. (1) THC and O-1602 promote the expression of activation receptors in the target cell (detailed information can be found in <a href="#app1-receptors-03-00007" class="html-app">Supplementary Table S3</a>). (2) Most cannabinoids (CBD, THC, O-1602, AEA) have been shown to regulate intracellular Ca<sup>2+</sup> levels in multiple cell types. (3) Cannabinoids have different effects on cytokine production and release. THC, CBD, and JWH133 decrease IFN-γ, IL-12, and TNF-α production, whereas AEA, AA, and O-1602 promote IL-12, IFN-γ, and TNF-α production. WIN55-212-2 and AEA promote cytokine production and release, whereas THC and JWH-133 inhibit cytokine production. (4) O-1602 enhances Granzyme B content in lytic granules, whereas CBD decreases Granzyme B content. (5) O-1602 favors NK degranulation. (6) CBD and THC have been shown to inhibit the NK chemotactic stimuli produced by target cells. (7) Cannabinoids modify the balance between activator and inhibitor proteins in target cells (further discussed in <a href="#sec4dot5-receptors-03-00007" class="html-sec">Section 4.5</a>). (8) Cannabinoids exert direct cytotoxic effects on several cancer types [<a href="#B113-receptors-03-00007" class="html-bibr">113</a>,<a href="#B114-receptors-03-00007" class="html-bibr">114</a>].</p>
Full article ">Figure 6
<p>Activatory and inhibitory interactions, modulated by cannabinoids in NK and target cells. Green: modifications in these interactions result in activation of NK cells. Red: modifications in these interactions result in inhibition of NK cells. Names of altered proteins are set in colored and bold font.</p>
Full article ">
Previous Issue
Next Issue
Back to TopTop